Nevro’s product is now the only spinal cord stimulation system labeled to treat the condition, the company said.
The FDA approval came after the company conducted a 12-month study into its system’s treatment of back pain. The company said study participants saw improvements in pain relief, quality of life and a reduction in daily opioid use compared to conventional treatments.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
